Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03

AUTHORS

Udo Holtick, Marco Herling, Natali Pflug, Geothy Chakupurakal, Silke Leitzke, Dominik Wolf, Michael Hallek, Christof Scheid, Jens M. Chemnitz

ABSTRACT

The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol. We retrospectively analyzed 130 consecutive patients with high-risk or relapsed AML after aSCT following FLAMSA conditioning at our center. Fifty-eight patients were treated with FLAMSA/treosulfan due to age and/or comorbidities. Seventy-two patients were treated with FLAMSA/TBI. Median age of patients treated with FLAMSA/treosulfan was 60 years compared to 46 years in those treated with FLAMSA/TBI. The cumulative incidence of a non-relapse mortality at 4 years was 28% in FLAMSA/treosulfan patients as compared to 13% in FLAMSA/TBI. Cumulative incidence of relapse was higher in patients treated with FLAMSA/TBI (46 vs. 32%). This difference was even more prominent for patients treated in blast persistence prior to transplant (relapse incidence 70% for TBI vs. 35% for treosulfan). The overall and relapse-free survival rates at 4 years were 47 and 41%, respectively, for patients treated with FLAMSA/TBI as compared to 43 and 40% in patients treated with FLAMSA/treosulfan. These data indicate an anti-leukemic activity by FLAMSA/treosulfan especially in patients with a blast persistence prior to transplant. Older age was an independent factor for a higher non-relapse mortality. Translating FLAMSA/treosulfan to younger patients, a lower non-relapse mortality, and an improved anti-leukemic activity might add up to improved overall survival. Randomized studies are required to demonstrate an improved efficacy of treosulfan- versus TBI-based FLAMSA conditioning. More... »

PAGES

479-487

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4

DOI

http://dx.doi.org/10.1007/s00277-016-2887-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007456209

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27909887


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Alkylating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Busulfan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation Conditioning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Whole-Body Irradiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holtick", 
        "givenName": "Udo", 
        "id": "sg:person.01060152106.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060152106.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herling", 
        "givenName": "Marco", 
        "id": "sg:person.01046626565.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046626565.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pflug", 
        "givenName": "Natali", 
        "id": "sg:person.0775410503.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775410503.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chakupurakal", 
        "givenName": "Geothy", 
        "id": "sg:person.0776253454.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776253454.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leitzke", 
        "givenName": "Silke", 
        "id": "sg:person.01167664514.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167664514.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Bonn", 
          "id": "https://www.grid.ac/institutes/grid.10388.32", 
          "name": [
            "Department III of Internal Medicine, University of Bonn, Bonn, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolf", 
        "givenName": "Dominik", 
        "id": "sg:person.014553451012.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014553451012.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hallek", 
        "givenName": "Michael", 
        "id": "sg:person.01025161256.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025161256.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scheid", 
        "givenName": "Christof", 
        "id": "sg:person.01312015730.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312015730.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chemnitz", 
        "givenName": "Jens M.", 
        "id": "sg:person.01126003571.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126003571.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bmt.2015.297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000925323", 
          "https://doi.org/10.1038/bmt.2015.297"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-10-4165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002613179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-015-2349-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005008575", 
          "https://doi.org/10.1007/s00277-015-2349-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428190701671051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006880760"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1993.03510010063030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008473572"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-11-3615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008819249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.62.7273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016119976"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.48.8114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018190408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2012.070235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025546715"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.3429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026375599"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-05-2004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027035706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/ejh.12615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031702566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2003-03-0855", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034662194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1705965", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035841647", 
          "https://doi.org/10.1038/sj.bmt.1705965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2013.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036134746", 
          "https://doi.org/10.1038/bmt.2013.185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-011-1253-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037372318", 
          "https://doi.org/10.1007/s00277-011-1253-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moh.0b013e3283309647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044469666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moh.0b013e3283309647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044469666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moh.0b013e3283309647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044469666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044565530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1704784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050128567", 
          "https://doi.org/10.1038/sj.bmt.1704784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.2000.02196.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056733260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10245330701214285", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058358190"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.12.049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076834181", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1988.6.10.1562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079525316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083204471", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03", 
    "datePublishedReg": "2017-03-01", 
    "description": "The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol. We retrospectively analyzed 130 consecutive patients with high-risk or relapsed AML after aSCT following FLAMSA conditioning at our center. Fifty-eight patients were treated with FLAMSA/treosulfan due to age and/or comorbidities. Seventy-two patients were treated with FLAMSA/TBI. Median age of patients treated with FLAMSA/treosulfan was 60\u00a0years compared to 46\u00a0years in those treated with FLAMSA/TBI. The cumulative incidence of a non-relapse mortality at 4\u00a0years was 28% in FLAMSA/treosulfan patients as compared to 13% in FLAMSA/TBI. Cumulative incidence of relapse was higher in patients treated with FLAMSA/TBI (46 vs. 32%). This difference was even more prominent for patients treated in blast persistence prior to transplant (relapse incidence 70% for TBI vs. 35% for treosulfan). The overall and relapse-free survival rates at 4\u00a0years were 47 and 41%, respectively, for patients treated with FLAMSA/TBI as compared to 43 and 40% in patients treated with FLAMSA/treosulfan. These data indicate an anti-leukemic activity by FLAMSA/treosulfan especially in patients with a blast persistence prior to transplant. Older age was an independent factor for a higher non-relapse mortality. Translating FLAMSA/treosulfan to younger patients, a lower non-relapse mortality, and an improved anti-leukemic activity might add up to improved overall survival. Randomized studies are required to demonstrate an improved efficacy of treosulfan- versus TBI-based FLAMSA conditioning.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00277-016-2887-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1018247", 
        "issn": [
          "1269-3286", 
          "1279-8509"
        ], 
        "name": "Annals of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "96"
      }
    ], 
    "name": "Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML", 
    "pagination": "479-487", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2383efb33993cdb76c2494692526325dd4575e739d3e99675078080540a7e675"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27909887"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9107334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-016-2887-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007456209"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-016-2887-4", 
      "https://app.dimensions.ai/details/publication/pub.1007456209"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87100_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00277-016-2887-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'


 

This table displays all metadata directly associated to this object as RDF triples.

279 TRIPLES      21 PREDICATES      72 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-016-2887-4 schema:about N0b659e10c5fc4e5d8dd652ea5a0d86ae
2 N13103f4ac6014b94b2c01c6a6ca41da4
3 N20c2f6f3bb5a4f20827da94b7fdf9676
4 N2f083f0eaed24f8dac2eabaa73c7a161
5 N4bebdeda27174971952ad3dd65b71d8b
6 N4fa5715e1f994deb9b8ccd5bcdffee87
7 N504d092ea3b8421fa65e82339e50a8a5
8 N6d9efaae01524f29a8921fd37d702cdb
9 N8997d786a93f4ac18606ae2d86c3b6a7
10 N94f5d0fd0d5c4b4b84ee0aa8ed2c5eab
11 N9fcdb144e03947179c16785793731df1
12 Nbb89a79b177646ed8ddfe862e21898e9
13 Nc390205890ac4454a64591475069d745
14 Nc9d4d8a26cd34390886801d1e7c9edc6
15 Nd009a366c01f4f16bf034638175ce051
16 Nd9dcc78525874fbc92c53ff7fe5bf085
17 Ne135fa0548b44672aeb8db69c8f5765e
18 Nf332dab224f948b9a80f605869033074
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N3bbcb9aa90794a25976f1d9e95253646
22 schema:citation sg:pub.10.1007/s00277-011-1253-9
23 sg:pub.10.1007/s00277-015-2349-4
24 sg:pub.10.1038/bmt.2013.185
25 sg:pub.10.1038/bmt.2015.297
26 sg:pub.10.1038/sj.bmt.1704784
27 sg:pub.10.1038/sj.bmt.1705965
28 https://app.dimensions.ai/details/publication/pub.1076834181
29 https://app.dimensions.ai/details/publication/pub.1083204471
30 https://doi.org/10.1001/jama.1993.03510010063030
31 https://doi.org/10.1046/j.1365-2141.2000.02196.x
32 https://doi.org/10.1080/10245330701214285
33 https://doi.org/10.1080/10428190701671051
34 https://doi.org/10.1097/moh.0b013e3283309647
35 https://doi.org/10.1111/ejh.12615
36 https://doi.org/10.1182/blood-2002-11-3615
37 https://doi.org/10.1182/blood-2003-03-0855
38 https://doi.org/10.1182/blood-2005-05-2004
39 https://doi.org/10.1182/blood-2005-10-4165
40 https://doi.org/10.1200/jco.1988.6.10.1562
41 https://doi.org/10.1200/jco.2002.12.049
42 https://doi.org/10.1200/jco.2005.07.061
43 https://doi.org/10.1200/jco.2009.23.3429
44 https://doi.org/10.1200/jco.2013.48.8114
45 https://doi.org/10.1200/jco.2015.62.7273
46 https://doi.org/10.3324/haematol.2012.070235
47 schema:datePublished 2017-03
48 schema:datePublishedReg 2017-03-01
49 schema:description The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol. We retrospectively analyzed 130 consecutive patients with high-risk or relapsed AML after aSCT following FLAMSA conditioning at our center. Fifty-eight patients were treated with FLAMSA/treosulfan due to age and/or comorbidities. Seventy-two patients were treated with FLAMSA/TBI. Median age of patients treated with FLAMSA/treosulfan was 60 years compared to 46 years in those treated with FLAMSA/TBI. The cumulative incidence of a non-relapse mortality at 4 years was 28% in FLAMSA/treosulfan patients as compared to 13% in FLAMSA/TBI. Cumulative incidence of relapse was higher in patients treated with FLAMSA/TBI (46 vs. 32%). This difference was even more prominent for patients treated in blast persistence prior to transplant (relapse incidence 70% for TBI vs. 35% for treosulfan). The overall and relapse-free survival rates at 4 years were 47 and 41%, respectively, for patients treated with FLAMSA/TBI as compared to 43 and 40% in patients treated with FLAMSA/treosulfan. These data indicate an anti-leukemic activity by FLAMSA/treosulfan especially in patients with a blast persistence prior to transplant. Older age was an independent factor for a higher non-relapse mortality. Translating FLAMSA/treosulfan to younger patients, a lower non-relapse mortality, and an improved anti-leukemic activity might add up to improved overall survival. Randomized studies are required to demonstrate an improved efficacy of treosulfan- versus TBI-based FLAMSA conditioning.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N6ea1fa941ecf4a3ab586a73a341af529
54 Nff57b73aa617436997e52871c14c16fb
55 sg:journal.1018247
56 schema:name Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML
57 schema:pagination 479-487
58 schema:productId N2655ed0eea2747d69a81bb46770e738f
59 N36280a821b8443209ce8068f608631d7
60 N9dca7f7e00984dc28535e214782c81a3
61 Nd6f6637c6d4b43c3964238f60d8dff85
62 Ne8d87296ce1844119acbd5384a86b602
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007456209
64 https://doi.org/10.1007/s00277-016-2887-4
65 schema:sdDatePublished 2019-04-11T12:24
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N8c39106923064ab0951a0cb16f55de0c
68 schema:url https://link.springer.com/10.1007%2Fs00277-016-2887-4
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N0b659e10c5fc4e5d8dd652ea5a0d86ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Follow-Up Studies
74 rdf:type schema:DefinedTerm
75 N13103f4ac6014b94b2c01c6a6ca41da4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Female
77 rdf:type schema:DefinedTerm
78 N20c2f6f3bb5a4f20827da94b7fdf9676 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Whole-Body Irradiation
80 rdf:type schema:DefinedTerm
81 N2655ed0eea2747d69a81bb46770e738f schema:name readcube_id
82 schema:value 2383efb33993cdb76c2494692526325dd4575e739d3e99675078080540a7e675
83 rdf:type schema:PropertyValue
84 N2f083f0eaed24f8dac2eabaa73c7a161 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Treatment Outcome
86 rdf:type schema:DefinedTerm
87 N36280a821b8443209ce8068f608631d7 schema:name dimensions_id
88 schema:value pub.1007456209
89 rdf:type schema:PropertyValue
90 N3bbcb9aa90794a25976f1d9e95253646 rdf:first sg:person.01060152106.45
91 rdf:rest Nb8793d690a824dadbf4be079afedc06d
92 N3cdbdb1384844569b6a7f90d7ea4458c rdf:first sg:person.01025161256.58
93 rdf:rest Nb7e74965472d4d4db04eba947b9c446c
94 N4088e6adedb84314aa4fa6b6ff6448fb rdf:first sg:person.0776253454.97
95 rdf:rest N82c3be3dcbec4327b6452458ef792aa7
96 N4bebdeda27174971952ad3dd65b71d8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Transplantation, Homologous
98 rdf:type schema:DefinedTerm
99 N4fa5715e1f994deb9b8ccd5bcdffee87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Adult
101 rdf:type schema:DefinedTerm
102 N504d092ea3b8421fa65e82339e50a8a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Retrospective Studies
104 rdf:type schema:DefinedTerm
105 N6d9efaae01524f29a8921fd37d702cdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Transplantation Conditioning
107 rdf:type schema:DefinedTerm
108 N6ea1fa941ecf4a3ab586a73a341af529 schema:issueNumber 3
109 rdf:type schema:PublicationIssue
110 N82c3be3dcbec4327b6452458ef792aa7 rdf:first sg:person.01167664514.20
111 rdf:rest Nb89656b6ea8e45aea0eafda1222ad305
112 N8997d786a93f4ac18606ae2d86c3b6a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Antineoplastic Agents, Alkylating
114 rdf:type schema:DefinedTerm
115 N8c39106923064ab0951a0cb16f55de0c schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N94f5d0fd0d5c4b4b84ee0aa8ed2c5eab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Hematopoietic Stem Cell Transplantation
119 rdf:type schema:DefinedTerm
120 N9dca7f7e00984dc28535e214782c81a3 schema:name doi
121 schema:value 10.1007/s00277-016-2887-4
122 rdf:type schema:PropertyValue
123 N9fcdb144e03947179c16785793731df1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 Nb5204218aed84d95bdce797842d5ff39 rdf:first sg:person.0775410503.46
127 rdf:rest N4088e6adedb84314aa4fa6b6ff6448fb
128 Nb7e74965472d4d4db04eba947b9c446c rdf:first sg:person.01312015730.26
129 rdf:rest Nc10d9711e5e7495baceb53eb43f5215b
130 Nb8793d690a824dadbf4be079afedc06d rdf:first sg:person.01046626565.60
131 rdf:rest Nb5204218aed84d95bdce797842d5ff39
132 Nb89656b6ea8e45aea0eafda1222ad305 rdf:first sg:person.014553451012.26
133 rdf:rest N3cdbdb1384844569b6a7f90d7ea4458c
134 Nbb89a79b177646ed8ddfe862e21898e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Aged
136 rdf:type schema:DefinedTerm
137 Nc10d9711e5e7495baceb53eb43f5215b rdf:first sg:person.01126003571.55
138 rdf:rest rdf:nil
139 Nc390205890ac4454a64591475069d745 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 Nc9d4d8a26cd34390886801d1e7c9edc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Survival Rate
144 rdf:type schema:DefinedTerm
145 Nd009a366c01f4f16bf034638175ce051 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Young Adult
147 rdf:type schema:DefinedTerm
148 Nd6f6637c6d4b43c3964238f60d8dff85 schema:name nlm_unique_id
149 schema:value 9107334
150 rdf:type schema:PropertyValue
151 Nd9dcc78525874fbc92c53ff7fe5bf085 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Risk Factors
153 rdf:type schema:DefinedTerm
154 Ne135fa0548b44672aeb8db69c8f5765e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Leukemia, Myeloid, Acute
156 rdf:type schema:DefinedTerm
157 Ne8d87296ce1844119acbd5384a86b602 schema:name pubmed_id
158 schema:value 27909887
159 rdf:type schema:PropertyValue
160 Nf332dab224f948b9a80f605869033074 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Busulfan
162 rdf:type schema:DefinedTerm
163 Nff57b73aa617436997e52871c14c16fb schema:volumeNumber 96
164 rdf:type schema:PublicationVolume
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
169 schema:name Oncology and Carcinogenesis
170 rdf:type schema:DefinedTerm
171 sg:journal.1018247 schema:issn 1269-3286
172 1279-8509
173 schema:name Annals of Hematology
174 rdf:type schema:Periodical
175 sg:person.01025161256.58 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
176 schema:familyName Hallek
177 schema:givenName Michael
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025161256.58
179 rdf:type schema:Person
180 sg:person.01046626565.60 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
181 schema:familyName Herling
182 schema:givenName Marco
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046626565.60
184 rdf:type schema:Person
185 sg:person.01060152106.45 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
186 schema:familyName Holtick
187 schema:givenName Udo
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060152106.45
189 rdf:type schema:Person
190 sg:person.01126003571.55 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
191 schema:familyName Chemnitz
192 schema:givenName Jens M.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126003571.55
194 rdf:type schema:Person
195 sg:person.01167664514.20 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
196 schema:familyName Leitzke
197 schema:givenName Silke
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167664514.20
199 rdf:type schema:Person
200 sg:person.01312015730.26 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
201 schema:familyName Scheid
202 schema:givenName Christof
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312015730.26
204 rdf:type schema:Person
205 sg:person.014553451012.26 schema:affiliation https://www.grid.ac/institutes/grid.10388.32
206 schema:familyName Wolf
207 schema:givenName Dominik
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014553451012.26
209 rdf:type schema:Person
210 sg:person.0775410503.46 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
211 schema:familyName Pflug
212 schema:givenName Natali
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775410503.46
214 rdf:type schema:Person
215 sg:person.0776253454.97 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
216 schema:familyName Chakupurakal
217 schema:givenName Geothy
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776253454.97
219 rdf:type schema:Person
220 sg:pub.10.1007/s00277-011-1253-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037372318
221 https://doi.org/10.1007/s00277-011-1253-9
222 rdf:type schema:CreativeWork
223 sg:pub.10.1007/s00277-015-2349-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005008575
224 https://doi.org/10.1007/s00277-015-2349-4
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/bmt.2013.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036134746
227 https://doi.org/10.1038/bmt.2013.185
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/bmt.2015.297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000925323
230 https://doi.org/10.1038/bmt.2015.297
231 rdf:type schema:CreativeWork
232 sg:pub.10.1038/sj.bmt.1704784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050128567
233 https://doi.org/10.1038/sj.bmt.1704784
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/sj.bmt.1705965 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035841647
236 https://doi.org/10.1038/sj.bmt.1705965
237 rdf:type schema:CreativeWork
238 https://app.dimensions.ai/details/publication/pub.1076834181 schema:CreativeWork
239 https://app.dimensions.ai/details/publication/pub.1083204471 schema:CreativeWork
240 https://doi.org/10.1001/jama.1993.03510010063030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008473572
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1046/j.1365-2141.2000.02196.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1056733260
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1080/10245330701214285 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058358190
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1080/10428190701671051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006880760
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1097/moh.0b013e3283309647 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044469666
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1111/ejh.12615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031702566
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1182/blood-2002-11-3615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008819249
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1182/blood-2003-03-0855 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034662194
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1182/blood-2005-05-2004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027035706
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1182/blood-2005-10-4165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002613179
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1200/jco.1988.6.10.1562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079525316
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1200/jco.2002.12.049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203203
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1200/jco.2005.07.061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044565530
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1200/jco.2009.23.3429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026375599
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1200/jco.2013.48.8114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018190408
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.2015.62.7273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016119976
271 rdf:type schema:CreativeWork
272 https://doi.org/10.3324/haematol.2012.070235 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025546715
273 rdf:type schema:CreativeWork
274 https://www.grid.ac/institutes/grid.10388.32 schema:alternateName University of Bonn
275 schema:name Department III of Internal Medicine, University of Bonn, Bonn, Germany
276 rdf:type schema:Organization
277 https://www.grid.ac/institutes/grid.6190.e schema:alternateName University of Cologne
278 schema:name BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany
279 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...